Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy

Phase 4CompletedNCT01980550

National Institute on Drug Dependence, China250 enrolled

Overview

Nicotine replacement treatment (NRT) can be efficacious for smoking cessation, but used by only a minority of smokers in China. Pharmacogenetic matching may improve treatment outcomes for NRT in subgroups of smokers. The investigators evaluated the efficacy and safety of sublingual nicotine tablets (SNT) for smoking cessation and the association of catechol-O-methyltransferase (COMT) genotype with efficacy in this smoking cessation trial among Chinese smokers.

All subjects provided written informed consent after a full explanation of the protocol design.

Study Type

INTERVENTIONAL

Allocation

Masking

DOUBLE

Enrollment

250

Conditions

Nicotine Dependence

Interventions

sublingual nicotineDRUG

The nicotine sublingual tablet is Smokers were recommended to use one or two tablets per hour, up to a maximum of 20 tablets per day. Subjects were advised to use the full treatment dose for 4 weeks. After this time-point, treatment could be tapered off up to the 8-week visit. During the next 4-week follow-up phase, no further medication was dispensed. Staff, who dispensed medications, were not involved in treating the subjects. During each patient visit, the importance of adequate dosing with study medication was emphasized. The medication was free of charge. In addition, all participants received six sessions of standardized behavioral group counseling focusing on self-monitoring and behavioral modification approaches.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects motivated to stop smoking and Han Chinese * aged 20-70 years who lived in the Haidian District of Beijing * smoke ≥10 cigarettes/day * have smoked for ≥3 years * carbon monoxide (CO) level ≥10 p.p.m. in exhaled air Exclusion Criteria: * a history of "Diagnostic and Statistical Manual of Mental Disorders-fourth Edition" (DSM-IV) psychiatric disorder * alcohol abuse and other drug abuse * with pathological changes in the floor of their mouth * cardiovascular disease * taking psychotropic medications * using other forms of tobacco or any other NRT products during the last 6 months * pregnant or breast-feeding

Outcomes

Primary Outcomes

Changes in the exhaled carbon monoxide (CO) level during the 12-week study

Time frame: The first was 1 day before quit day (baseline), followed by visits after 1, 2, 4, 6 and 8 weeks at the end of treatment (EOT), with a final follow-up visit at 12 weeks.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.